A phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study analyzing the safety, tolerability, and pharmacokinetics of NB-4746 in healthy volunteers
Latest Information Update: 19 Sep 2024
At a glance
- Drugs NB 4746 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Nura Bio
Most Recent Events
- 17 Sep 2024 Status changed from recruiting to completed, according to Nura Bio Media Release.
- 28 Aug 2023 New trial record